Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > Sirona Lab financing

<< Previous

Bullboard Posts

Next >>

Post by tylerreddickon Jan 24, 2024 9:34am

159 Views

Post# 35842635

Sirona Lab financing

Along with any "private" funds providing future financing for Sirona Labs, the company should do a rights offering for existing shareholders, so we can decide if we want to benefit fully from its potential.
SBM may keep a "majority" interest, but that may only mean 51%, which would mean we lose 49% of the value of GlycoProteMim.
JMO

<< Previous

Bullboard Posts

Next >>

Gold vs. bitcoin, where should you invest?